BETTERLIFE PHARMA INC - BETRF STOCK NEWS

BetterLife Pharma Inc. has announced the publication of a study on its lead candidate, BETR-001 (2-bromo-LSD), in the journal Cell Reports. The study demonstrates that BETR-001 has distinct pharmacological advantages over LSD, including non-hallucinogenic effects and a safer cardiovascular profile. BETR-001 showed partial agonism at the 5-HT2A receptor while lacking 5-HT2B agonism. Additionally, it induced neuroplasticity and promoted coping behavior in animal models of depression and anxiety. BetterLife aims to begin human clinical trials for BETR-001 by the end of 2023, indicating potential therapeutic applications for mood disorders.

BetterLife Pharma Inc. has engaged Bloom Burton Securities for strategic advisory services aimed at supporting its growth and clinical trial efforts. The company has made notable progress in developing BETR-001, a non-hallucinogenic LSD derivative, which is currently undergoing preclinical studies and manufacturing preparations. BetterLife also highlighted its achievements in advancing therapies for mental health disorders and viral infections. Regulatory studies and patent applications are underway to bolster the company's intellectual property portfolio. This collaboration is expected to enhance its financing capabilities as it progresses toward clinical trials.

BetterLife Pharma has successfully closed a non-brokered private placement, issuing 3,160,000 common shares at USD$0.15 each, raising gross proceeds of USD$474,000. The funds will aid in working capital and advancing pre-clinical and clinical programs. Additionally, a convertible debtholder converted C$250,000 of debt into 1,540,135 common shares at C$0.20 per share, boosting the company's equity. Negev Capital's investment supports BetterLife's development of BETR-001, targeting neuropsychiatric disorders, and highlights the company's promising prospects in the psychedelic medication arena.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced its lead compound, BETR-001, will be presented at the ACNP Conference from December 4-7, 2022. Dr. Argel Aguilar-Valles from Carleton University will share promising preclinical data showing BETR-001's acute and long-term anti-depressant effects and its promotion of neuroplasticity. CEO Dr. Ahmad Doroudian emphasized BETR-001's non-hallucinogenic nature, offering a regulatory advantage for future trials. IND-enabling studies are underway, with a potential IND filing and human trials targeted for mid-2023.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced the filing of a PCT patent application and a U.S. application for LSD derivatives, including 2-bromo-LSD, aimed at treating various neuropsychiatric disorders. The new compound, BETR-001, is non-hallucinogenic and not regulated as a controlled substance, allowing for easier development. BetterLife is progressing in GMP manufacturing and preclinical studies, expecting to file an IND for BETR-001 and commence Phase 1 trials in H1 2023. The CEO highlighted the potential of BETR-001 in addressing mental health conditions.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced plans to submit a key research publication on BETR-001, a proprietary 2-bromo-LSD, to a prestigious peer-reviewed journal by the end of September 2022. The research features preclinical studies highlighting BETR-001's non-hallucinogenic profile and its neuroplasticity and anti-depressant effects compared to LSD. CEO Ahmad Doroudian emphasized the potential therapeutic benefits of BETR-001, with human clinical trials projected to start in 2023. BetterLife is focused on treating neuro-psychiatric disorders with innovative compounds like BETR-001.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) is advancing its development of BETR-001, a non-hallucinogenic LSD analog, which has shown promising results in enhancing neuroplasticity and treating mental disorders. A recent study indicates that BETR-001 promotes structural plasticity in neurons, likely contributing to its antidepressant effects. This compound is unique as it is unregulated, allowing for potential self-administration. BetterLife is also developing BETR-002 for anxiety disorders and exploring a drug candidate for viral infections, including COVID-19.

BetterLife Pharma (CSE: BETR / OTCQB: BETRF) announced funding for research into the anti-depressant effects of its drug candidate BETR-001, a non-hallucinogenic LSD derivative. Collaborating with Carleton University, the project aims to explore BETR-001's mechanism of action in preclinical depression models. BETR-001 targets severe depression and cluster headaches, with plans for an Investigational New Drug (IND) application. BetterLife also holds patents for BETR-002, aimed at treating anxiety disorders, and is pursuing development of a candidate for viral infections.

BetterLife Pharma Inc. has announced that its lead compound, BETR-001, will be showcased at the FENS Forum in Paris from July 9-13, 2022. This presentation, led by Dr. Vern Lewis, will highlight preclinical data demonstrating the anti-depressant properties of BETR-001, a non-hallucinogenic LSD derivative. BetterLife's unique synthesis patent allows for easier access and self-administration, aiming to treat neuropsychiatric disorders without the regulatory constraints of traditional LSD. The company is also advancing BETR-002, targeting anxiety-related conditions.